海普瑞(002399)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002399 海普瑞

已收盘 12-16 15:00:00

{"stockData":{"symbol":"002399","market":"SZ","secType":"STK","nameCN":"海普瑞","latestPrice":11.67,"timestamp":1765868601000,"preClose":11.67,"halted":0,"volume":2826002,"delay":0,"changeRate":0,"floatShares":1247000000,"shares":1467000000,"eps":0.2864,"marketStatus":"已收盘","change":0,"latestTime":"12-16 15:00:00","open":11.69,"high":11.69,"low":11.54,"amount":32798600,"amplitude":0.0129,"askPrice":11.68,"askSize":39,"bidPrice":11.67,"bidSize":40,"shortable":0,"etf":0,"ttmEps":0.2864,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765935000000},"marketStatusCode":5,"adr":0,"adjPreClose":11.67,"symbolType":"stock","openAndCloseTimeList":[[1765848600000,1765855800000],[1765861200000,1765868400000]],"highLimit":12.84,"lowLimit":10.5,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1467296204,"isCdr":false,"pbRate":1.38,"roa":"--","peRate":40.747207,"roe":"4.51%","epsLYR":0.4408,"committee":-0.25724,"marketValue":17123000000,"turnoverRate":0.0023,"status":2,"hkstockBrief":{"symbol":"09989","market":"HK","secType":"STK","nameCN":"海普瑞","latestPrice":5.12,"timestamp":1765872500011,"preClose":5.14,"halted":0,"volume":1085000,"delay":0,"premium":"-60.34"},"floatMarketCap":14555000000},"requestUrl":"/m/hq/s/002399/tweets","defaultTab":"tweets","newsList":[{"id":"2591398582","title":"海普瑞选举张平为职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2591398582","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591398582?lang=zh_cn&edition=full","pubTime":"2025-12-16 18:39","pubTimestamp":1765881570,"startTime":"0","endTime":"0","summary":"海普瑞（002399/09989）发布公告，公司于2025年12月16日召开2025年第一次临时股东会，审议通过了关于修订《公司章程》的相关议案。根据修订后的《公司章程》，公司董事会将一个非独立董事席位调整为职工董事席位。张平被选举为公司第六届董事会职工董事，任期至第六届董事会届满之日止。2025年前三季度，海普瑞实现收入41.94亿元，归母净利润5.54亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163593149586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","002399","BK0188","BK0070","BK1191","09989"],"gpt_icon":0},{"id":"2589276842","title":"较A股折价60%，肝素即将走出下行周期海普瑞(09989)现抄底信号？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589276842","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589276842?lang=zh_cn&edition=full","pubTime":"2025-12-06 14:18","pubTimestamp":1765001919,"startTime":"0","endTime":"0","summary":"今年10月30日，海普瑞披露了公司2025年第三季度财报。归属于上市公司股东的净利润5.54亿元，同比下降29.04%。这便是导致此轮生猪下行周期以及肝素下行周期的重要原因。2025年1月，出口价格环比大幅上涨27%。而这一预期已在海普瑞A股上有所反应，目前海普瑞A股股价12.04元，较去年低点6.64元已拉升81.63%。相较之下，海普瑞港股股价虽在同样区间内也有大幅上涨，但仍较A股股价折价60%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09989","002399","399300","BK0239","BK1191","BK0070","BK0188","159982"],"gpt_icon":0},{"id":"2585498536","title":"海普瑞（002399）披露召开2025年第一次临时股东会通知，11月24日股价上涨1.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585498536","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585498536?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:28","pubTimestamp":1763994491,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，海普瑞报收于11.71元，较前一交易日上涨1.21%，最新总市值为171.82亿元。近日，深圳市海普瑞药业集团股份有限公司发布公告，宣布将于2025年12月16日召开2025年第一次临时股东会，会议由董事会召集，现场会议地点为深圳市南山区南海大道3031号兰赫美特酒店二楼宴会厅。股权登记日为2025年12月8日。其中，《关于取消监事会暨修订<公司章程>及配套议事规则的议案》需经出席股东会的股东所持表决权的三分之二以上通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002399","BK0239","BK0070","BK0188","09989","BK1191"],"gpt_icon":0},{"id":"2585467195","title":"海普瑞：关于独立董事任期届满离任暨补选独立董事的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2585467195","media":"证券日报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585467195?lang=zh_cn&edition=full","pubTime":"2025-11-24 21:36","pubTimestamp":1763991416,"startTime":"0","endTime":"0","summary":"证券日报网讯11月24日晚间，海普瑞发布公告称，根据有关规定，独立董事在同一上市公司连续任职时间不得超过六年。公司现任独立董事吕川先生连续任职时间即将届满六年。根据前述规定，届满离任后，吕川先生将不再担任包括公司第六届董事会独立董事及董事会专门委员会相应职务（包括提名委员会主任委员、审计委员会委员及战略委员会委员）在内的任何职务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511243573239378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK1191","002399","09989","BK0070","BK0239"],"gpt_icon":0},{"id":"2585465856","title":"海普瑞(09989)：建议选举浦洪为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2585465856","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585465856?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:31","pubTimestamp":1763980279,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞(09989)发布公告，董事会建议选举浦洪为独立非执行董事，惟须待股东于临时股东大会上批准后方可作实。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","002399","BK0070","BK0188","BK0239","09989"],"gpt_icon":0},{"id":"2584135924","title":"股市必读：海普瑞（002399）11月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2584135924","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584135924?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:28","pubTimestamp":1763573293,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，海普瑞报收于12.26元，下跌0.73%，换手率0.25%，成交量3.16万手，成交额3885.55万元。董秘最新回复投资者： 您好！请问截至10月31日公司股东人数是多少，谢谢！交易信息汇总资金流向11月18日主力资金净流出551.62万元；游资资金净流出114.52万元；散户资金净流入666.14万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000000681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","09989","002399","BK1191","BK0188"],"gpt_icon":0},{"id":"2580417858","title":"海普瑞（002399）2025年三季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2580417858","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580417858?lang=zh_cn&edition=full","pubTime":"2025-11-01 06:41","pubTimestamp":1761950498,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期海普瑞发布2025年三季报。根据财报显示，海普瑞增收不增利。截至本报告期末，公司营业总收入41.94亿元，同比上升3.09%，归母净利润5.54亿元，同比下降29.04%。按单季度数据看，第三季度营业总收入13.77亿元，同比上升11.82%，第三季度归母净利润1.32亿元，同比上升13.14%。本次财报公布的各项数据指标表现一般。去年的净利率为11.83%，算上全部成本后，公司产品或服务的附加值一般。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100007483.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","09989","BK0188","BK0239","BK0070","002399"],"gpt_icon":0},{"id":"2579141625","title":"图解海普瑞三季报：第三季度单季净利润同比增长13.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579141625","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579141625?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:26","pubTimestamp":1761827177,"startTime":"0","endTime":"0","summary":"证券之星消息，海普瑞2025年三季报显示，前三季度公司主营收入41.94亿元，同比上升3.09%；归母净利润5.54亿元，同比下降29.04%；扣非净利润5.52亿元，同比上升28.69%；其中2025年第三季度，公司单季度主营收入13.77亿元，同比上升11.82%；单季度归母净利润1.32亿元，同比上升13.14%；单季度扣非净利润1.26亿元，同比上升26.54%；负债率27.46%，投资收益2566.79万元，财务费用-1.57亿元，毛利率31.53%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000041062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09989","002399"],"gpt_icon":0},{"id":"2579631118","title":"海普瑞：前三季度净利润约5.53亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579631118","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579631118?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:15","pubTimestamp":1761815700,"startTime":"0","endTime":"0","summary":"每经AI快讯，10月30日，海普瑞(09989.HK)在港交所发布公告称，2025年前三季度营收约41.94亿元，同比增3.09%；归属于上市公司股东的净利润约5.54亿元，同比降29.04%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-10-30/doc-infvskcs4177499.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-10-30/doc-infvskcs4177499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09989","002399"],"gpt_icon":0},{"id":"2563101020","title":"海普瑞(09989)公布中期业绩 归母净利约4.22亿元 同比减少36.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563101020","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563101020?lang=zh_cn&edition=full","pubTime":"2025-08-29 17:03","pubTimestamp":1756458190,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞(09989)公布2025年中期业绩，收入约27.91亿元，同比减少1.3%;母公司持有者的应占溢利约4.22亿元，同比减少36.4%;每股盈利0.29元。公告称，净利润同比有所下降，主要由于2024年同期受大额一次性投资收益正向影响，对本报期利润同比变化影响较大。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1338524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002399","BK0070","BK0188","BK0239","09989","BK1191"],"gpt_icon":0},{"id":"2553428942","title":"异动快报：海普瑞（002399）7月21日11点26分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2553428942","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553428942?lang=zh_cn&edition=full","pubTime":"2025-07-21 11:30","pubTimestamp":1753068638,"startTime":"0","endTime":"0","summary":"证券之星7月21日盘中消息，11点26分海普瑞触及涨停板。目前价格13.82，上涨10.03%。其所属行业化学制药目前上涨。领涨股为一品红。该股为肝素，化学原料药，创新药概念热股，当日肝素概念上涨1.46%，化学原料药概念上涨1.14%，创新药概念上涨1.03%。7月18日的资金流向数据方面，主力资金净流出186.5万元，占总成交额3.23%，游资资金净流出126.23万元，占总成交额2.18%，散户资金净流入312.73万元，占总成交额5.41%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072100010233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","09989","002399","BK1191","BK0188"],"gpt_icon":0},{"id":"2552644463","title":"海普瑞(002399.SZ)：H1710完成I期临床试验首例受试者入组及首次给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2552644463","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552644463?lang=zh_cn&edition=full","pubTime":"2025-07-18 16:34","pubTimestamp":1752827646,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞 公告，公司自主研发的创新候选药物注射用H1710I期临床试验已完成首例受试者入组及首次给药。H1710通过抑制乙酰肝素酶的活性和表达，展现出抗肿瘤作用。本次临床试验为开放、剂量递增的Ia期临床研究，评价H1710在晚期实体瘤患者中的安全性、耐受性和初步抗肿瘤活性，为H1710的首次人体试验，计划在三家研究中心开展，预计入组约36名患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1319434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK1191","BK1576","BK1583","09989","BK0239","03347","BK1141","002399","BK0070"],"gpt_icon":0},{"id":"2550651116","title":"海普瑞新提交2件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2550651116","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550651116?lang=zh_cn&edition=full","pubTime":"2025-07-10 05:07","pubTimestamp":1752095259,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日深圳市海普瑞药业集团股份有限公司新提交2件商标注册申请。商标申请详情如下：今年以来深圳市海普瑞药业集团股份有限公司新申请注册商标6件，截止目前公司共持有注册商标149件，另有12件商标尚在注册申请中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071000003375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002399","BK0188","BK1191","BK0070","09989","BK0239"],"gpt_icon":0},{"id":"2549107347","title":"海普瑞新提交2件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2549107347","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549107347?lang=zh_cn&edition=full","pubTime":"2025-07-06 05:07","pubTimestamp":1751749637,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日深圳市海普瑞药业集团股份有限公司新提交2件商标注册申请。商标申请详情如下：今年以来深圳市海普瑞药业集团股份有限公司新申请注册商标2件，截止目前公司共持有注册商标149件，另有8件商标尚在注册申请中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070600000702.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0239","BK0188","002399","BK0070","09989"],"gpt_icon":0},{"id":"2548001150","title":"海普瑞：坪山园区预灌封制剂生产线获EMA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2548001150","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548001150?lang=zh_cn&edition=full","pubTime":"2025-07-01 20:51","pubTimestamp":1751374289,"startTime":"0","endTime":"0","summary":"证券之星消息，海普瑞06月30日在投资者关系平台上答复投资者关心的问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070100035454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002399","BK0188","BK0070","BK1191","09989","BK0239"],"gpt_icon":0},{"id":"2548001166","title":"海普瑞：公司将持续聚焦主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2548001166","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548001166?lang=zh_cn&edition=full","pubTime":"2025-07-01 20:51","pubTimestamp":1751374288,"startTime":"0","endTime":"0","summary":"证券之星消息，海普瑞(002399)06月30日在投资者关系平台上答复投资者关心的问题。投资者提问：公司有进军其他行业的打算吗？毕竟现在很多国家重点扶持的行业发展势头强劲，公司有没有考虑过鸡蛋不要放在一个篮子里？海普瑞回复：您好，公司将持续聚焦主业，巩固全球销售网络和全肝素产业链垂直打通的领先优势，加大市场拓展力度，探索商业合作模式，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070100035453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09989","BK0188","BK0070","002399","BK1191"],"gpt_icon":0},{"id":"2545847686","title":"港股异动 | 海普瑞(09989)午前涨超3% 近日收到EMA签发关于依诺肝素钠注射液新增生产商的批准通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2545847686","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545847686?lang=zh_cn&edition=full","pubTime":"2025-06-24 11:42","pubTimestamp":1750736554,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海普瑞午前涨超3%，截至发稿，涨3.09%，报5.33港元，成交额872.01万港元。消息面上，海普瑞发布公告，公司近日收到欧洲药品管理局签发的关于依诺肝素钠注射液新增生产商的批准通知。据介绍，海普瑞坪山园区新建预灌封制剂生产线项目于2022年正式启动，首期新建三条预灌封生产线设计产能为3.3亿支╱年，其按照中国、欧美药品法规标准设计建造，用于生产依诺肝素钠预灌封注射液。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1308820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002399","BK1191","EMA","BK4081","BK0070","BK0239","09989","BK0188"],"gpt_icon":0},{"id":"2545149658","title":"海普瑞(09989)将于7月7日派发末期股息每10股2.5元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545149658","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545149658?lang=zh_cn&edition=full","pubTime":"2025-06-23 16:32","pubTimestamp":1750667556,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞(09989)发布公告，该公司将于2025年7月7日派发截至2024年12月31日止年度的末期股息每10股2.5元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1308387.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","09989","BK0239","BK0188","BK1191","002399"],"gpt_icon":0},{"id":"2517193729","title":"海普瑞：公司将持续加强市值管理工作争取为股东带来更好回报","url":"https://stock-news.laohu8.com/highlight/detail?id=2517193729","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517193729?lang=zh_cn&edition=full","pubTime":"2025-03-05 20:51","pubTimestamp":1741179096,"startTime":"0","endTime":"0","summary":"证券之星消息，海普瑞(002399)03月04日在投资者关系平台上答复投资者关心的问题。投资者提问：工资如何维护投资者的利益？是否看好公司未来前景？能否推行员工持股股计划四期，能否回购公司股份注销？能否推动高管增持股份计划？能否2024年度分红扩股？海普瑞回复：您好，公司始终坚持聚焦核心主业，提升公司内在价值，我们将持续加强市值管理工作，促进公司投资价值合理反映公司质量，争取为股东带来更好的回报。谢谢您的关注。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030500038393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK1191","09989","BK0239","002399","BK0070"],"gpt_icon":0},{"id":"2517195619","title":"海普瑞：公司专注主业已建立全球销售网络和全肝素产业链领先优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2517195619","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517195619?lang=zh_cn&edition=full","pubTime":"2025-03-05 20:51","pubTimestamp":1741179092,"startTime":"0","endTime":"0","summary":"证券之星消息，海普瑞03月04日在投资者关系平台上答复投资者关心的问题。公司是否会进行投资？海普瑞回复：您好，公司专注主业，在肝素领域，我们已建立全球销售网络和全肝素产业链垂直打通的领先优势，核心产品依诺肝素钠制剂远销逾40个国家及地区。同时，我们持续探索合适机遇，如建立并推进与正大天晴、永太药业的商业合作，助力中国药企出海。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030500038389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK1191","002399","09989","BK0070","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765922276424,"stockEarnings":[{"period":"1week","weight":-0.0193},{"period":"1month","weight":-0.0709},{"period":"3month","weight":-0.0782},{"period":"6month","weight":0.0108},{"period":"1year","weight":0.0555},{"period":"ytd","weight":0.1148}],"compareEarnings":[{"period":"1week","weight":-0.0217},{"period":"1month","weight":-0.0415},{"period":"3month","weight":-0.0133},{"period":"6month","weight":0.1376},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.1411}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳市海普瑞药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"2010-05-06","address":"广东省深圳市南山区松坪山郎山路21号","registeredCapital":"146729万元","survey":"　　深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投资，开发及商业化。公司的主要产品是依诺肝素钠制剂、肝素钠、依诺肝素钠原料药、大分子药物CDMO服务。","listedPrice":148},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海普瑞(002399)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海普瑞(002399)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海普瑞,002399,海普瑞股票,海普瑞股票老虎,海普瑞股票老虎国际,海普瑞行情,海普瑞股票行情,海普瑞股价,海普瑞股市,海普瑞股票价格,海普瑞股票交易,海普瑞股票购买,海普瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海普瑞(002399)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海普瑞(002399)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}